OBJECTIVE AND DESIGN: We designed a study to detect downstream phosphorylation targets of PKCβ in MCP-1-induced human monocytes. METHODS: Two-dimensional gel electrophoresis was performed for monocytes treated with MCP-1 in the presence or absence of PKCβ antisense oligodeoxyribonucleotides (AS-ODN) or a PKCβ inhibitor peptide, followed by phospho- and total protein staining. Proteins that stained less intensely with the phospho-stain, when normalized to the total protein stain, in the presence of PKCβ AS-ODN or the PKCβ inhibitor peptide, were sequenced. RESULTS: Of the proteins identified, vimentin was consistently identified using both experimental approaches. Upon (32)P-labeling and vimentin immunoprecipitation, increased phosphorylation of vimentin was observed in MCP-1 treated monocytes as compared to the untreated monocytes. Both PKCβ AS-ODN and the PKCβ inhibitor reduced MCP-1-induced vimentin phosphorylation. The IP of monocytes with anti-vimentin antibody and immunoblotting with a PKCβ antibody revealed that increased PKCβ becomes associated with vimentin upon MCP-1 activation. Upon MCP-1 treatment, monocytes were shown to secrete vimentin and secretion depended on PKCβ expression and activity. CONCLUSIONS: We conclude that vimentin, a major intermediate filament protein, is a phosphorylation target of PKCβ in MCP-1-treated monocytes and that PKCβ phosphorylation is essential for vimentin secretion. Our recently published studies have implicated vimentin as a potent stimulator of the innate immune receptor Dectin-1 as reported by Thiagarajan et al. (Cardiovasc Res 99:494-504, 2013). Taken together our findings suggest that inhibition of PKCβ regulates vimentin secretion and, thereby, its interaction with Dectin-1 and downstream stimulation of superoxide anion production. Thus, PKCβ phosphorylation of vimentin likely plays an important role in propagating inflammatory responses.
OBJECTIVE AND DESIGN: We designed a study to detect downstream phosphorylation targets of PKCβ in MCP-1-induced human monocytes. METHODS: Two-dimensional gel electrophoresis was performed for monocytes treated with MCP-1 in the presence or absence of PKCβ antisense oligodeoxyribonucleotides (AS-ODN) or a PKCβ inhibitor peptide, followed by phospho- and total protein staining. Proteins that stained less intensely with the phospho-stain, when normalized to the total protein stain, in the presence of PKCβ AS-ODN or the PKCβ inhibitor peptide, were sequenced. RESULTS: Of the proteins identified, vimentin was consistently identified using both experimental approaches. Upon (32)P-labeling and vimentin immunoprecipitation, increased phosphorylation of vimentin was observed in MCP-1 treated monocytes as compared to the untreated monocytes. Both PKCβ AS-ODN and the PKCβ inhibitor reduced MCP-1-induced vimentin phosphorylation. The IP of monocytes with anti-vimentin antibody and immunoblotting with a PKCβ antibody revealed that increased PKCβ becomes associated with vimentin upon MCP-1 activation. Upon MCP-1 treatment, monocytes were shown to secrete vimentin and secretion depended on PKCβ expression and activity. CONCLUSIONS: We conclude that vimentin, a major intermediate filament protein, is a phosphorylation target of PKCβ in MCP-1-treated monocytes and that PKCβ phosphorylation is essential for vimentin secretion. Our recently published studies have implicated vimentin as a potent stimulator of the innate immune receptor Dectin-1 as reported by Thiagarajan et al. (Cardiovasc Res 99:494-504, 2013). Taken together our findings suggest that inhibition of PKCβ regulates vimentin secretion and, thereby, its interaction with Dectin-1 and downstream stimulation of superoxide anion production. Thus, PKCβ phosphorylation of vimentin likely plays an important role in propagating inflammatory responses.
Authors: G Penton-Rol; N Polentarutti; W Luini; A Borsatti; R Mancinelli; A Sica; S Sozzani; A Mantovani Journal: J Immunol Date: 1998-04-15 Impact factor: 5.422
Authors: S Sozzani; M Locati; D Zhou; M Rieppi; W Luini; G Lamorte; G Bianchi; N Polentarutti; P Allavena; A Mantovani Journal: J Leukoc Biol Date: 1995-05 Impact factor: 4.962
Authors: Praveena S Thiagarajan; Valentin P Yakubenko; Deena H Elsori; Satya P Yadav; Belinda Willard; Carmela D Tan; E René Rodriguez; Maria Febbraio; Martha K Cathcart Journal: Cardiovasc Res Date: 2013-05-13 Impact factor: 10.787
Authors: Evis Harja; Loredana G Bucciarelli; Yan Lu; David M Stern; Yu Shan Zou; Ann Marie Schmidt; Shi-Fang Yan Journal: Circ Res Date: 2003-12-11 Impact factor: 17.367
Authors: Tomoyuki Fujita; Tomohiro Asai; Martin Andrassy; David M Stern; David J Pinsky; Yu Shan Zou; Morihito Okada; Yoshifumi Naka; Ann Marie Schmidt; Shi-Fang Yan Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: Evis Harja; Jong Sun Chang; Yan Lu; Michael Leitges; Yu Shan Zou; Ann Marie Schmidt; Shi-Fang Yan Journal: FASEB J Date: 2008-11-26 Impact factor: 5.191